Posted by Michael Wonder on 19 Jun 2019
Atomoxetine – delay in change of funded brand and open access
19 June 2019 - PHARMAC is advising all interested parties that there will be a delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions.
The listing of the Generic Partners’ brand of atomoxetine capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg) has been delayed and will now be listed from 1 November 2019; and the restrictions will be removed from atomoxetine from that date. The current funded brand, Strattera, will remain listed until 1 April 2020.
